NEW YORK (GenomeWeb News) – BiOasis Technologies and the University of British Columbia will collaborate to develop and test a biomarker assay for Alzheimer's disease, the company said today.
The goal of the collaboration is to develop and test concentration levels of the p97 protein in blood using an enzyme-linked immunosorbent assay test to diagnose Alzheimer's. The firms said that the "quick and accurate" test would help doctors diagnose the disease and monitor the effectiveness of therapeutics.
The one-year agreement between UBC and the Vancouver, BC-based company will attempt to correlate the presence of p97 in tissues with other markers of Alzheimer's disease, such as the presence of senile plaques, and to correlate that expression with other markers from human bioinformatic databases.
"Having a test, such as that afforded by the BiOasis product, could have significant benefit, because there are treatable diseases that can mimic Alzheimer's, and in addition, treatments currently available for Alzheimer's, although somewhat limited in their efficacy, have the greatest chances of benefiting a patient when started early," BiOasis Senior Medical Advisor Michael Shannon said in a statement.